<DOC>
	<DOC>NCT01883518</DOC>
	<brief_summary>The purpose of this study is to achieving a six-month progression free survival (PFS) of patients receiving autologous dendritic cell vaccine (ADKV) loaded with allogeneic tumor lysate expression of cancer-testis antigens (CTA) in patients with soft tissue sarcomas</brief_summary>
	<brief_title>Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Connective and Soft Tissue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>age of 18 or older ECOG performance score 0 or 1 Histologically proven soft tissue sarcoma Unresectable or metastatic soft tissue sarcoma Ability to give written informed consent Objective measured and measurable tumor lesions The failure of standard therapy Adequate amount of material for genetic research No active or chronic infection with HIV, Hepatitis B or Hepatitis C Men/Women of childbearing potential must use adequate contraception Hematology, liver function and renal function lab tests within required parameters Untreated or uncontrolled brain metastases. History of other active malignancy within last 2 years, except adequately treated other soft tissue sarcoma. Autoimmune disease (vitiligo is not a basis for exclusion). Serious uncontrolled medical disorder or active infection that would impede treatment. Underlying medical or psychiatric condition that would cause administration vaccine Any nononcology vaccine therapy up to 1 month before or after any dose of vaccine Concomitant therapy with IL2, interferon, other nonstudy immunotherapy, or cytotoxic chemotherapy; immunesuppressive agents within 30 days of registration; other investigational therapies; chronic use of systemic corticosteroids (however, a low stable dose steroid for mild brain edema or adrenal insufficiency is allowed; topical and inhaled standard dose corticosteroids are allowed). Dementia or significantly altered mental status that would prohibit understanding or rendering of informed consent and compliance with protocol requirements. Pregnant or breastfeeding women. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g. infectious) illness.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Fibrosarcoma</keyword>
	<keyword>Neurofibrosarcoma</keyword>
	<keyword>Histiocytoma</keyword>
	<keyword>Histiocytoma, Malignant Fibrous</keyword>
	<keyword>Chondrosarcoma</keyword>
	<keyword>Synovial Sarcoma</keyword>
	<keyword>Leiomyosarcoma</keyword>
	<keyword>Liposarcoma</keyword>
	<keyword>Myosarcoma</keyword>
	<keyword>Rhabdomyosarcoma</keyword>
	<keyword>Sarcoma, Alveolar Soft Part</keyword>
	<keyword>NY-ESO-1</keyword>
	<keyword>MAGE</keyword>
	<keyword>MAGE A3</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>